Alzheimer's Clinical Trials Consortium

Non-AD Dementia Committee

Bradley Boeve, MD

by

Co-Chair, Non-AD Dementia Committee. Dr. Boeve is a consultant in the Department of Neurology and Center for Sleep Medicine at Mayo Clinic in Rochester, Minnesota, and is Professor of Neurology in the Mayo Clinic College of Medicine and Science. He is recognized with the distinction of the Little Family Foundation Professorship in Lewy Body Dementia. He also serves as Chair of the Division of Behavioral Neurology. His clinical and research interests include MCI/AD as well as the non-Alzheimer’s degenerative dementias, with particular interests in the frontotemporal lobar degeneration-spectrum disorders (e.g., FTD+/-ALS, PPA, CBS, PSP) and Lewy body disease-spectrum disorders (e.g., DLB, PDD, RBD+MCI, and RBD). He is a member of the Medical Advisory Council of the Association for Frontotemporal Degeneration, the International Society for Frontotemporal Dementias, the FTD Prevention Initiative, the Scientific Advisory Council of the Lewy Body Dementia Association (LBDA), the LBDA Research Centers of Excellence Program, and International REM Sleep Behavior Disorder Study Group. He is co-PI or co-I on several national/international consortia focused on FTLD- and LBD-spectrum disorders. He is funded by the NIH, the Little Family Foundation, and the Mangurian Foundation.

Adam Boxer, MD

by

Adam L. Boxer, MD, PhD is the Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF).  He co-chairs the ACTC Non-Alzheimer’s Dementia Committee.  At UCSF, he directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center.  Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43.  He is the Principal Investigator of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium, a collaborative project funded by the National Institutes of Health to create an 18 center North American research network to support the development of new therapies for FTLD. He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD.  He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in FTLD spectrum disorders, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, and salsalate for PSP.  He co-chairs the FTLD Treatment Study Group (FTSG) and the PSP Research Roundtable, academic-industry collaborative groups working to speed the development of new therapies for FTLD, CBD and PSP.